Previous 10 | Next 10 |
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2019 Canada NewsWire HOUSTON, TX and VANCOUVER, May 10, 2019 HOUSTON , TX and VANCOUVER , May 10, 2019 /CNW/ - ESSA Pharma Inc. (TSX-V: EPI, NASDAQ: EPIX), ...
Preclinical Data Highlighting Therapeutic Potential of EPI-7386 Presented at 2019 American Urological Association Annual Meeting Canada NewsWire HOUSTON, TX and VANCOUVER, May 4, 2019 HOUSTON, TX and VANCOUVER , May 4, 2019 /CNW/ - ESSA Pharma Inc. (Nasdaq: EPIX; TSX-V:...
The following slide deck was published by ESSA Pharma Inc. in conjunction with this Read more ...
Noteworthy events during the latter part of the week of April 28 - May 4 for healthcare investors. More news on: UroGen Pharma Ltd., ESSA Pharma Inc., EyePoint Pharmaceuticals, Inc., Healthcare stocks news, , Read more ...
ESSA Pharma to Attend Bloom Burton & Co. Healthcare Investor Conference 2019 ESSA Pharma to Attend Bloom Burton & Co. Healthcare Investor Conference 2019 Canada NewsWire HOUSTON and VANCOUVER, April 25, 2019 HOUSTON and VANCOUVER , April 25, 2019 /CNW/ - ...
ESSA Pharma Announces Abstract Presentation at the 2019 American Urological Association Annual Meeting Canada NewsWire HOUSTON and VANCOUVER, April 17, 2019 HOUSTON and VANCOUVER , April 17, 2019 /CNW/ - ESSA Pharma Inc. (TSX-V: EPI; Nasdaq: EPIX), a pharmaceutical...
HOUSTON , TX and VANCOUVER , April 12, 2019 /PRNewswire/ - ESSA Pharma Inc. (TSX-V: EPI; Nasdaq: EPIX) ("ESSA" or the "Corporation") announced that, pursuant to its stock option plan, it has granted incentive stock options to directors and officers, employees and consults of th...
HOUSTON, TX and VANCOUVER , March 28, 2019 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (TSX-V: EPI; Nasdaq: EPIX), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced its lead clinical candidate, EPI-738...
HOUSTON and VANCOUVER , March 28, 2019 /PRNewswire/ - ESSA Pharma Inc. (TSX-V: EPI; Nasdaq: EPIX), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the nomination of EPI-7386 as the lead clinical candidate for the ...
HOUSTON, TX and VANCOUVER , March 18, 2019 /PRNewswire/ - ESSA Pharma Inc. (TSX-V: EPI; Nasdaq: EPIX) ("ESSA" or the "Company"), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer announced the Company will be presenting Oppenheimer 29 ...
News, Short Squeeze, Breakout and More Instantly...
ESSA Pharma to Present at the JonesHealthcare Seaside Summit Canada NewsWire SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC , July 8, 2024 /CNW/ - ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on de...
ESSA Pharma to Present at the Jefferies Global Healthcare Conference Canada NewsWire SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC , May 30, 2024 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focus...